Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SORRENTO THERAPEUTICS, INC.

(SRNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
5.89(c) 5.96(c) 5.53(c) 5.51(c) 4.9471 Last
5 930 616 5 630 985 6 540 962 4 241 817 8 027 498 Volume
-0.84% +1.19% -7.21% -0.36% -10.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 58,1 M - -
Net income 2021 -367 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,41x
Yield 2021 -
Sales 2022 193 M - -
Net income 2022 -131 M - -
Net Debt 2022 - - -
P/E ratio 2022 -12,8x
Yield 2022 -
Capitalization 1 646 M 1 646 M -
Capi. / Sales 2021 28,3x
Capi. / Sales 2022 8,54x
Nbr of Employees 502
Free-Float 88,8%
More Financials
Company
Sorrento Therapeutics, Inc. is a clinical-stage antibody-centric biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical-stage... 
More about the company
Ratings of Sorrento Therapeutics, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SORRENTO THERAPEUTICS, INC.
11/30Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx..
AQ
11/30Sorrento Publishes an Abivertinib Teaser Entitled 'Abivertinib - a Franchise Oral Thera..
AQ
11/29SORRENTO THERAPEUTICS : Abivertinib November 2021
PU
11/29SORRENTO THERAPEUTICS : Abivertinib – A Broad Pipeline for Cancer, COVID-19 and Auto..
PU
11/29SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/29Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchis..
AQ
11/22Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests fo..
GL
11/22Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests fo..
CI
11/18Sorrento Therapeutics, Inc. Approves the Appointment of Elizabeth A. Czerepak as Direct..
CI
11/18SORRENTO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
11/16Lee's Pharmaceutical Arm Enrolls First Patient in Clinical Trial of Melanoma Treatment ..
MT
11/15Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening..
AQ
11/15Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivert..
AQ
11/14SORRENTO THERAPEUTICS : November 2021 Corporate Presentation
PU
11/12Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening..
GL
More news
News in other languages on SORRENTO THERAPEUTICS, INC.
11/16La branche pharmaceutique de Lee recrute son premier patient dans le cadre d'un essai c..
11/03Sorrento Therapeutics obtient l'approbation du Brésil pour le test Covistix COVID-19 ; ..
11/01Le partenaire de licence de Sorrento dépose une demande de nouveau médicament en Chine ..
10/27Les autorités réglementaires chinoises vont examiner la demande de nouveau médicament d..
10/20Sorrento Therapeutics obtient le marquage CE et l'enregistrement du dispositif pour le ..
More news
Analyst Recommendations on SORRENTO THERAPEUTICS, INC.
More recommendations
Chart SORRENTO THERAPEUTICS, INC.
Duration : Period :
Sorrento Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SORRENTO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 5,51 $
Average target price 26,00 $
Spread / Average Target 372%
EPS Revisions
Managers and Directors
Henry H. Ji Chairman, President & Chief Executive Officer
Najjam Asghar Chief Financial & Accounting Officer, SVP
Mike A. Royal Chief Medical Officer
Stephen L Klincewicz VP-Pharmacovigilance & Clinical Operations
Yue Wu Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SORRENTO THERAPEUTICS, INC.-18.97%1 646
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982